Tag Archives: Big data

Hot Investor Mandate 3: Investment Arm of Major China Genomics Company Looks for Complementary Early-Stage Genomics & Big Data/AI Technologies

15 Mar

A branch of a subsidiary of a major genomics sequencing company in China is actively seeking technologies from the US, Canada, and China that will complement what they currently have. In addition to direct investments, the firm often functions as a strategic partner that can help provide a technology platform for a startup or even integrate the new technology into their system. The firm also provides access to their large marketing team once the product is developed to help the startup during their commercialization phase. The firm is currently interested in early stage companies: usually at seed to series A and is rather flexible as to the financing terms. Additionally, the firm is willing to work through either partnerships or direct investments.

The firm is actively seeking new genomics technologies. Currently, the firm is interested in any technology within diagnostics, digital health, and medtech that has a focus on genomics. Within the diagnostics and medtech sectors, the firm is particularly interested in sequencing technologies currently, but is willing to see all early stage genomics-based technologies within these sectors. For digital health, the firm is interested in companies involved in big data and AI that already have algorithms that can utilize the large pool of genomics data that the firm currently has access to.

When investing, the firm likes to take an active role in the company and prefers taking board seats but does not require a board seat. Otherwise, the firm prefers to work with companies that the firm can work with and help develop into either a potential integration or a productive partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Big Data in Drug Discovery: 5 Experts Share Their Thoughts at RESI Boston

7 Sep

By Michael Quigley, VP of Investor Research, LSN

mike-2To reduce the massive costs associated with getting a new drug approved, many startups, large pharma companies, venture funds, and others are looking to big data for a solution. These firms are researching, partnering, and investing into machine learning and artificial intelligence systems that scour through massive drug and target libraries to more quickly identify potential candidates than a team of researchers could. These technologies are leveraging all kinds of scientific and medical data including chemical, biologic, genomic and clinical datasets to best identify candidates. Companies are touting their tech promises “years” of savings and lower failure rates in research that can now be done through advanced algorithms. This may seem like quite the promise, but if you look at the number and size of deals in the space just in the past year, it’s clear that big players are listening (1, 2, 3, 4, 5, 6).

At RESI Boston this September 26th we are bringing together a panel of 5 experts in this space to discuss their thoughts on the challenges and opportunities that the use of Big Data in Drug Discovery currently faces. These speakers include a promising company with an emerging drug discovery technology, a massive CRO, and three venture funds, all actively working in this space. Look below to see the speakers for yourself. This is another cutting-edge session you won’t want to miss!

  • Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec (moderator)
  • Gini Deshpande, Founder and Chief Executive Officer, NuMedii, Inc.
  • Millie Liu, Founding Partner, Managing Director, Procyon Ventures
  • Dylan Morris, Partner, CRV
  • Annie Hazlehurst, Founder, Faridan
  1. http://www.fiercebiotech.com/medtech/gsk-taps-baltimore-s-insilico-for-ai-based-drug-discovery
  2. https://www.reuters.com/article/us-astrazeneca-ai-berg/astrazeneca-taps-ai-for-drug-discovery-in-deal-with-berg-idUSKCN1B81G1
  3. http://www.koreabiomed.com/news/articleView.html?idxno=1254
  4. http://www.prnewswire.com/news-releases/wuxi-nextcode-ai-points-to-new-therapeutic-approaches-to-cardiovascular-disease-and-cancer-in-yale-nature-study-300457412.html
  5. http://www.wired.co.uk/article/benevolent-ai-london-unicorn-pharma-startup
  6. http://www.prnewswire.com/news-releases/numedii-inc-announces-new-partnership-to-discover-and-advance-new-treatments-for-idiopathic-pulmonary-fibrosis-300437651.html

Panel Announcement: Big Data in Healthcare

20 Oct

By Christine A. Wu, Senior Research Analyst, LSN


LSN is pleased to publish its first panel announcement for RESI SF 2017: Big Data in Healthcare. On January 10th, a panel of five expert healthcare investors will speak regarding why they’re looking for big data investment opportunities, how they identify technologies that will have an impact on the healthcare system landscape, and what early-stage fundraising companies in this exciting new vertical can do to get a foot in their doors.

The Big Data in Healthcare panel will comprise of the following panelists:

The big data space has increasingly become exciting with its potential to transform healthcare through its cross-correlation of a number of broad applications – computer vision, machine learning, patient medical records, disease diagnoses, mental health trends and proposed therapies, as well as many other spaces in healthcare. If you haven’t yet, be sure to register now for this tremendous educational opportunity in this booming space, while also having the chance to meet valuable investors in-person.



Big Data, Digital Medicine, and A View of the Future at RESI X

22 Sep

By Caitlin Kramer, Research Analyst, LSN


RESI X featured the arrival of a new panel session – Big Data in Healthcare.  If you were unable to attend, you will have another opportunity to hear insights from investors and influencers in the space at RESI SF on January 10th.

The panel, available for your viewing below, was moderated by Nicole Fisher (Founder & CEO, HHR Strategies) and featured the thoughts and experiences of:

Each discussed the unique approaches their firms take toward evaluating big data and software investment opportunities, how they partner with and shape start-up growth, and how the healthcare system landscape is (or is not) shifting to enable a realization of the big data vision.

A unique angle toward the healthcare system and policy was brought to the table by moderator Nicole Fisher, who works on Capitol Hill as a senior healthcare policy advisor, Forbes’ Contributor, and Founder and CEO of HHR Strategies.

At many points throughout the panel discussion, the conversation trended toward how data can improve healthcare delivery and outcomes. Emerging technologies blending healthcare, science, and data do not enter the same marketplace as other generalist tech software; instead they must interface with provider systems and policies in ways that are new and different from the existing therapeutic and device sectors. Morris gave an illustrative example of the “noise” created by this new relationship: he and his primary care physician ordered genetic tests, and faced with interpreting the 24 pages of results realized “neither of us are cardio-geneticists, so now what?” While the technologies advanced by new companies may provide actionable information, the health system will ultimately play a central role in their utilization and continued innovation in the space.

Entrepreneurs need to know that technology itself frequently takes a back seat to other aspects of a company. Getting blunt, de Winter shared: “The way investors think is driven by fear and greed. You want to think about how your idea specifically addresses the greed part of that equation.” Morris, an entrepreneur himself, had to transition away from his natural enthusiasm for the underlying science of a company when he began his career in venture capital. “The order of operations in the way we look at a company is market, then team, then the product, and then finally technology”, he said.

There is consensus that teams are central to accomplishing a company’s goals. Hazlehurst describes how oftentimes a company’s goal is to “translate science into software”. She goes on, “It’s a fun and challenging problem because the lifestyle and culture between the people building in these different domains is very different, and getting everyone you need working together is more than just a technical problem.” Deep and practical expertise in life sciences and software engineering are indeed vastly separate, and teams need to effectively coordinate internally and externally with strategics to formulate long-term visions.

With regard to the technology, two main aspects of big data technologies were touched upon: algorithms and data. Entrepreneurs may be surprised to learn that IP around algorithms is not a core focus of potential investors. Algorithms will change and evolve in response to higher quality or increased data. Therefore, a more important focus is access to high quality proprietary data through partnerships or through its generation as part of the platform. “We have now over 300 million individual patient records spanning 5-10 years, but that’s not enough and we still crave more”, said Pan.

Wearables, which continuously record certain metrics for individuals, inevitably enter conversations about health data. Their true utility to big data applications in healthcare is still unclear, although it is clear that in many respects they empower individuals to better understand and track their daily habits. Creating a distinction, and if necessary a distance, between digital health trends and rigorously validated data acquisition is important to avoiding hype cycles and fostering continued innovation in the field.

How we can ultimately arrive at the vision shared by entrepreneurs, investors, established companies, and individuals is explored in moderator Nicole Fisher’s recently authored whitepaper “The Digital Medicine Crystal Ball: Unlocking the Future of Real-Time, Precise, Effective, Healthcare”, published by EBD Group last month: “It is time we agree on defining and refining the meaning of digital medicine, particularly as it pertains to the toys versus the tools that will usher in a new age of healthcare. This will determine how the proper tools can lead to the most efficient and effective R&D process, strengthen the patient-physician relationship, and simultaneously enable individuals to become the CEO of their own health.1

Life Science Nation is proud to have hosted these thoughtful and influential individuals and the firms they represent, as well as the many inspiring entrepreneurs doing the heavy lifting to champion their technologies. Said Hazlehurst, “One of the beauties of investing in early stage companies is that you’re waiting for the day an entrepreneur is going to walk through your door and pitch you on something that’s really unique and disruptive.” To our life science entrepreneurs in the audience: get out there and do it. Many, like LSN, are here to help.

  1. Fisher, Nicole. The Digital Medicine Crystal Ball: Unlocking the Future of Real-Time, Precise, Effective, Healthcare. Publication. Carlsbad: EBD Group, 2016. 4.

%d bloggers like this: